Life-sciences industry perspective
Gilead is the life-sciences company that has developed sofosbuvir; a new medication licensed for the treatment of hepatitis C. Sofosbuvir can be combined with ribavirin, or ribavirin and interferon over different periods of time to treat the disease. The BOSON study is trying to find out which is the best treatment regime for patients who are infected with the genotype 3 variation of the hepatitis C virus.
For the development and delivery of the BOSON study, Gilead collaborated closely with the STOP-HCV consortium. This collaboration helped to ensure a successful outcome, as did using the Clinical Research Network’s study support mechanisms.
In this interview you’ll find out exactly why the UK’s performance on the BOSON study was head and shoulders above that of other countries involved in the trial across the globe.